Acrivon Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
ACRV$1.58-1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
As of the date of this Annual Report, none of our directors or executive officers maintains an active Rule 10b5-1 trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.